Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology.

Sechi E, Shosha E, Williams JP, Pittock SJ, Weinshenker BG, Keegan BM, Zalewski NL, Lopez-Chiriboga AS, Jitprapaikulsan J, Flanagan EP.

Neurology. 2019 Jun 24. pii: 10.1212/WNL.0000000000007828. doi: 10.1212/WNL.0000000000007828. [Epub ahead of print]

PMID:
31235660
2.

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.

Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, Geurts JJG, Paul F, Reich DS, Toosy AT, Traboulsee A, Wattjes MP, Yousry TA, Gass A, Lubetzki C, Weinshenker BG, Rocca MA.

Brain. 2019 Jun 17. pii: awz144. doi: 10.1093/brain/awz144. [Epub ahead of print]

PMID:
31209474
3.

Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up.

Petzold A, Woodhall M, Khaleeli Z, Tobin WO, Pittock SJ, Weinshenker BG, Vincent A, Waters P, Plant GT.

J Neurol Neurosurg Psychiatry. 2019 May 22. pii: jnnp-2019-320493. doi: 10.1136/jnnp-2019-320493. [Epub ahead of print]

PMID:
31118222
4.

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.

Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.

Lancet Neurol. 2019 Feb;18(2):185-197. doi: 10.1016/S1474-4422(18)30460-5. Review.

PMID:
30663608
5.

Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.

Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, Weinshenker BG, Shosha E, Lucchinetti CF, Fryer JP, Lopez-Chiriboga AS, Chen JC, Jitprapaikulsan J, McKeon A, Gadoth A, Keegan BM, Tillema JM, Naddaf E, Patterson MC, Messacar K, Tyler KL, Flanagan EP.

JAMA Neurol. 2018 Dec 21. doi: 10.1001/jamaneurol.2018.4053. [Epub ahead of print]

PMID:
30575890
6.

"A rose by any other name": does defining extreme phenotypes add to the management of multiple sclerosis?

Jolliffe EA, Weinshenker BG.

Ann Transl Med. 2018 Oct;6(20):396. doi: 10.21037/atm.2018.08.15. No abstract available.

7.

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

Nervenarzt. 2018 Dec;89(12):1388-1399. doi: 10.1007/s00115-018-0607-0. Review. German.

PMID:
30264269
8.

Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria.

Zalewski NL, Rabinstein AA, Krecke KN, Brown RD Jr, Wijdicks EFM, Weinshenker BG, Kaufmann TJ, Morris JM, Aksamit AJ, Bartleson JD, Lanzino G, Blessing MM, Flanagan EP.

JAMA Neurol. 2019 Jan 1;76(1):56-63. doi: 10.1001/jamaneurol.2018.2734.

PMID:
30264146
9.

Population-based study of "no evident disease activity" in MS.

Parks NE, Pittock SJ, Mandrekar J, Kantarci OH, Lucchinetti CF, Weinshenker BG, Keegan BM, Tobin WO, Tillema JM, Toledano M, Flanagan EP.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 16;5(6):e495. doi: 10.1212/NXI.0000000000000495. eCollection 2018 Nov.

10.

Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.

Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ.

Am J Ophthalmol. 2018 Nov;195:8-15. doi: 10.1016/j.ajo.2018.07.020. Epub 2018 Jul 26.

11.

Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease.

Keegan BM, Kaufmann TJ, Weinshenker BG, Kantarci OH, Schmalstieg WF, Paz Soldan MM, Flanagan EP.

Mult Scler. 2018 Oct;24(11):1445-1452. doi: 10.1177/1352458518781979. Epub 2018 Jul 26.

PMID:
30047830
12.

Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis.

Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Aksamit AJ, Krecke KN, Kaufmann TJ, Jolliffe EA, Zalewski NL, Zekeridou A, Wingerchuk DM, Jitprapaikulsan J, Flanagan EP.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):488-490. doi: 10.1136/jnnp-2018-318004. Epub 2018 Jul 21. No abstract available.

PMID:
30032117
13.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. Review.

14.

Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.

Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, McKeon A, Lennon VA, Leavitt JA, Tillema JM, Lucchinetti C, Keegan BM, Kantarci O, Khanna C, Jenkins SM, Spears GM, Sagan J, Pittock SJ.

Ophthalmology. 2018 Oct;125(10):1628-1637. doi: 10.1016/j.ophtha.2018.03.041. Epub 2018 Apr 30.

PMID:
29716788
15.

Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis.

Jitprapaikulsan J, Lopez Chiriboga AS, Flanagan EP, Fryer JP, McKeon A, Weinshenker BG, Pittock SJ.

JAMA Neurol. 2018 Jul 1;75(7):892-895. doi: 10.1001/jamaneurol.2018.0805. No abstract available.

16.

Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS.

Corboy JR, Weinshenker BG, Wingerchuk DM.

Neurology. 2018 Jun 12;90(24):1106-1112. doi: 10.1212/WNL.0000000000005574. Epub 2018 Apr 23. Review.

PMID:
29685920
17.

Spinal cord infarction: Clinical and imaging insights from the periprocedural setting.

Zalewski NL, Rabinstein AA, Krecke KN, Brown RD, Wijdicks EFM, Weinshenker BG, Doolittle DA, Flanagan EP.

J Neurol Sci. 2018 May 15;388:162-167. doi: 10.1016/j.jns.2018.03.029. Epub 2018 Mar 17.

PMID:
29627015
18.

Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.

Toledano M, Weinshenker BG, Kaufmann TJ, Parisi JE, Paz Soldán MM.

Mult Scler. 2019 Apr;25(5):709-714. doi: 10.1177/1352458518767045. Epub 2018 Mar 23.

PMID:
29570004
19.

A practical approach to the diagnosis of spinal cord lesions.

Mariano R, Flanagan EP, Weinshenker BG, Palace J.

Pract Neurol. 2018 Jun;18(3):187-200. doi: 10.1136/practneurol-2017-001845. Epub 2018 Mar 2. Review.

PMID:
29500319
20.

Cervical spinal cord atrophy: An early marker of progressive MS onset.

Zeydan B, Gu X, Atkinson EJ, Keegan BM, Weinshenker BG, Tillema JM, Pelletier D, Azevedo CJ, Lebrun-Frenay C, Siva A, Okuda DT, Kantarci K, Kantarci OH.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 22;5(2):e435. doi: 10.1212/NXI.0000000000000435. eCollection 2018 Mar.

21.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
22.

Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibody-Positive Meningoencephalitis.

Chen JJ, Aksamit AJ, McKeon A, Pittock SJ, Weinshenker BG, Leavitt JA, Morris PP, Flanagan EP.

J Neuroophthalmol. 2018 Sep;38(3):276-281. doi: 10.1097/WNO.0000000000000593.

PMID:
29210929
23.

Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management.

Shosha E, Pittock SJ, Flanagan E, Weinshenker BG.

Mult Scler. 2017 Dec;23(14):1808-1817. doi: 10.1177/1352458517740215. Review.

PMID:
29154728
24.

A population-based prospective study of optic neuritis.

Soelberg K, Jarius S, Skejoe H, Engberg H, Mehlsen JJ, Nilsson AC, Madsen JS, Reindl M, Wildemann B, Grauslund J, Kyvik KO, Smith TJ, Lillevang ST, Paul F, Weinshenker BG, Asgari N.

Mult Scler. 2017 Dec;23(14):1893-1901. doi: 10.1177/1352458517734070. Epub 2017 Oct 5.

PMID:
28980518
25.

Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - NO.

Tobin WO, Weinshenker BG.

Mult Scler. 2017 Aug;23(9):1190-1192. doi: 10.1177/1352458517702556. Epub 2017 Jul 4. No abstract available.

PMID:
28673112
26.

Elsberg syndrome: A rarely recognized cause of cauda equina syndrome and lower thoracic myelitis.

Savoldi F, Kaufmann TJ, Flanagan EP, Toledano M, Weinshenker BG.

Neurol Neuroimmunol Neuroinflamm. 2017 May 11;4(4):e355. doi: 10.1212/NXI.0000000000000355. eCollection 2017 Jul.

27.

Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.

Solomon AJ, Weinshenker BG.

Neurology. 2017 May 23;88(21):2067-2068. doi: 10.1212/WNL.0000000000003973. No abstract available.

PMID:
28533349
28.

Baló concentric sclerosis evolving from apparent tumefactive demyelination.

Hardy TA, Corboy JR, Weinshenker BG.

Neurology. 2017 May 30;88(22):2150-2152. doi: 10.1212/WNL.0000000000003990. Epub 2017 May 3. No abstract available. Erratum in: Neurology. 2017 Jul 25;89(4):411.

PMID:
28468846
29.

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder.

Asgari N, Flanagan EP, Fujihara K, Kim HJ, Skejoe HP, Wuerfel J, Kuroda H, Kim SH, Maillart E, Marignier R, Pittock SJ, Paul F, Weinshenker BG.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 21;4(4):e343. doi: 10.1212/NXI.0000000000000343. eCollection 2017 Jul.

30.

Neuromyelitis Spectrum Disorders.

Weinshenker BG, Wingerchuk DM.

Mayo Clin Proc. 2017 Apr;92(4):663-679. doi: 10.1016/j.mayocp.2016.12.014. Review.

PMID:
28385199
31.

Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.

Asgari N, Jarius S, Laustrup H, Skejoe HP, Lillevang ST, Weinshenker BG, Voss A.

Mult Scler. 2018 Mar;24(3):331-339. doi: 10.1177/1352458517699791. Epub 2017 Mar 22.

PMID:
28326889
32.

Myelitis in neuromyelitis optica spectrum disorder: The long and the short of it.

Flanagan EP, Weinshenker BG.

Mult Scler. 2017 Mar;23(3):360-361. doi: 10.1177/1352458517692888. No abstract available.

PMID:
28260418
33.

Variation in MS outcome: Race, place, or both?

Weinshenker BG, Lucas RM.

Neurology. 2017 Mar 28;88(13):1214-1215. doi: 10.1212/WNL.0000000000003776. Epub 2017 Feb 24. No abstract available.

PMID:
28235813
34.

Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.

Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Morris PP, Basal E, Honorat JA, Alfugham NB, Linnoila JJ, Weinshenker BG, Pittock SJ, McKeon A.

Ann Neurol. 2017 Feb;81(2):298-309. doi: 10.1002/ana.24881.

PMID:
28120349
35.

Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important.

Wingerchuk DM, Weinshenker BG.

Mult Scler. 2017 Feb;23(2):182-184. doi: 10.1177/1352458516688352. Epub 2017 Jan 12. No abstract available.

PMID:
28080211
36.

Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.

Zalewski NL, Morris PP, Weinshenker BG, Lucchinetti CF, Guo Y, Pittock SJ, Krecke KN, Kaufmann TJ, Wingerchuk DM, Kumar N, Flanagan EP.

J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):218-225. doi: 10.1136/jnnp-2016-314738. Epub 2016 Dec 2.

PMID:
27913626
37.

Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion.

Keegan BM, Kaufmann TJ, Weinshenker BG, Kantarci OH, Schmalstieg WF, Paz Soldan MM, Flanagan EP.

Neurology. 2016 Oct 18;87(16):1713-1719. Epub 2016 Sep 16.

38.

The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.

Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG.

Neurology. 2016 Sep 27;87(13):1393-9. doi: 10.1212/WNL.0000000000003152. Epub 2016 Aug 31.

39.

Disease modifying therapies for relapsing multiple sclerosis.

Wingerchuk DM, Weinshenker BG.

BMJ. 2016 Aug 22;354:i3518. doi: 10.1136/bmj.i3518. Review.

PMID:
27549763
40.

Central canal enhancement and the trident sign in spinal cord sarcoidosis.

Zalewski NL, Krecke KN, Weinshenker BG, Aksamit AJ, Conway BL, McKeon A, Flanagan EP.

Neurology. 2016 Aug 16;87(7):743-4. doi: 10.1212/WNL.0000000000002992. No abstract available.

PMID:
27527540
41.

Does early (treatment in) BENEFIT lead to late MS benefit?

Healy BC, Weinshenker BG.

Neurology. 2016 Sep 6;87(10):970-1. doi: 10.1212/WNL.0000000000003070. Epub 2016 Aug 10. No abstract available.

PMID:
27511185
42.

Atypical inflammatory demyelinating syndromes of the CNS.

Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG.

Lancet Neurol. 2016 Aug;15(9):967-981. doi: 10.1016/S1474-4422(16)30043-6. Review.

PMID:
27478954
43.

Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls.

Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen X, Weinshenker BG, Rodriguez M, Kantarci OH, Nelson H, Murray JA, Mangalam AK.

Sci Rep. 2016 Jun 27;6:28484. doi: 10.1038/srep28484.

44.

Posterior reversible encephalopathy syndrome is not associated with mutations in aquaporin-4.

Matiello M, Muralidharan R, Sun D, Rabinstein AA, Weinshenker BG.

Neurol Genet. 2015 Jul 16;1(2):e19. doi: 10.1212/NXG.0000000000000013. eCollection 2015 Aug.

45.

Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.

Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Robinson AB, Pittock SJ.

Ann Neurol. 2016 May;79(5):775-783. doi: 10.1002/ana.24617. Epub 2016 Apr 4.

46.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Tan CT, Mao Z, Qiu W, Hu X, Wingerchuk DM, Weinshenker BG.

Neurology. 2016 Feb 2;86(5):491-2. doi: 10.1212/WNL.0000000000002366. No abstract available.

PMID:
26833940
47.

Discriminating long myelitis of neuromyelitis optica from sarcoidosis.

Flanagan EP, Kaufmann TJ, Krecke KN, Aksamit AJ, Pittock SJ, Keegan BM, Giannini C, Weinshenker BG.

Ann Neurol. 2016 Mar;79(3):437-47. doi: 10.1002/ana.24582. Epub 2016 Feb 12.

PMID:
26677112
48.

What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?

Weinshenker BG.

Ann Neurol. 2016 Feb;79(2):204-5. doi: 10.1002/ana.24557. Epub 2016 Jan 14. No abstract available.

PMID:
26575334
49.

Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?

Weinshenker BG.

Mult Scler. 2015 Nov;21(13):1746-7. doi: 10.1177/1352458515603801. Epub 2015 Sep 11.

PMID:
26362899
50.

Stopping immunomodulatory medications in MS: Frequency, reasons and consequences.

Tobin WO, Weinshenker BG.

Mult Scler Relat Disord. 2015 Sep;4(5):437-443. doi: 10.1016/j.msard.2015.07.004. Epub 2015 Jul 8. Review. Erratum in: Mult Scler Relat Disord. 2016 Jan;5():105.

PMID:
26346792

Supplemental Content

Loading ...
Support Center